COMPLAINTS RESOLUTION PANEL DETERMINATION Complaints 2012-09-006 Finitro Australia website
Meeting held 21 March 2013
Complaint summary^
Complainants Ian Dalton
Advertiser Finitro B.V.
Subject matter of complaint Internet advertisement Type of determination Final
Sections of the Code, Regulations or Act found to have been breached*
Act section 42DL(1)(g)
Code sections 4(1)(b), 4(2)(a), 4(2)(c), 4(2)(g), 4(2)(h), 4(5), 5(2)
Sections of the Code, Regulations or Act found not to have been breached*
None
Sanctions Withdrawal of representations
Withdrawal of advertisement
* only sections of the Code, Act, or Regulations that were part of the complaint or were raised by the Panel are listed
The advertisement(s)^
1. The complaint concerned an advertisement published at the website australia.finitro.com and viewed by the complainant in September 2012.
2. The advertisement included representations such as “Finitro Forte Plus has led to amazing results in the treatment of arthritis, rheumatoid and other joint pain”, “Finitro Forte Plus is regarded as the most effective cure worldwide”, “Finitro Forte Plus includes Type II Collagen, Hyaluronic Acid, Glucosamine and Chondroitin for a life free of pain”, “helps to reverse the deterioration of cartilage that causes arthritis”, “inhibits the autoimmune response in people who suffer from rheumatism, which helps to reduce inflammation of the joints”, “also contains MSM and herbs that have a powerful anti-inflammatory effect so most people who take it notice a definite reduction in their joint pain in a matter of days”, “the most powerful remedy for chronic joint pain on the international market”, “type II collagen is the principal component of healthy cartilage and helps to prevent the surface of the cartilage from breaking down”, “the natural anti-inflammatory agents have a rapid calming effect, and the glucosamine and chondroitin stimulate the production of new cartilage and synovial fluid”, and “natural herbs have a calming effect on inflammation rapidly.”
3. It stated that “result[s] of independent research” were that “after 2 weeks you will experience less pain”, “after 4 weeks you will feel almost no pain in your joints. The cartilage begins to rebuild and you will see a slight improvement in the joint lubrication”, “after 8 weeks, the pain in your joints should disappear. The cartilage is being rebuilt and there is more joint lubrication”, “after 12 weeks, you not only will experience no more pain, but your joints should also move much smoother. The structuring of cartilage and joint lubrication are currently optimal”, “after continuous use of Finitro Forte Plus, the recovery of the cartilage and a life free of pain are guaranteed.”
4. An excerpt of the advertisement can be viewed in the relevant Appendix to this determination.
The product(s)
5. The advertisement promoted the product Finitro Forte Plus.
The advertiser(s)
6. The advertiser was Finitro B.V.
The complaint^
7. The complainant was Ian Dalton.
8. The complainant argued that the advertisement contained “unsubstantiated claims”. The Panel interpreted the complaint as raising possible breaches of sections 4(1)(b), 4(2)(a), and 4(2)(c) of the Code, and advised the advertiser of this interpretation.
Additional matters raised by the Panel
9. Under sub-regulation 42ZCAH(1), the Panel is empowered to raise matters other than those specified in the complaint, where the Panel is satisfied that the advertisement to which the complaint relates contains matter that is not mentioned in the complaint, which may contravene the Act, Regulations, or the Code in other ways. The Panel was so satisfied and raised the following additional matters:
a) Possible breaches of section 42DL(1)(g) of the Act, because the advertisement promotes Finitro Forte Plus for therapeutic use, when the product may not be included in the Register;
b) Possible breaches of sections 4(1)(b), 4(2)(a) and 4(2)(c) of the Code because of representations about the effect and benefits of the product made in the advertisement;
c) Possible breaches of sections 4(2)(g) and 4(2)(h) of the Code because of representations about “a life free of pain” and other representations about the effects of the advertised product, including the material headed “Result of independent research”;
d) Possible breaches of section 4(5) of the Code because of the claims that the product is the “most effective cure worldwide” and “the most powerful remedy for chronic joint pain on the international market”; and,
e) Possible breaches of section 5(2) of the Code because of the representation that “Finitro Forte Plus has led to amazing results in the treatment of arthritis, rheumatoid and other joint pain”.
The advertiser’s response to the complaint^
10.The advertiser stated that, in response to the complaint, they had modified the website. They did not otherwise respond to the particulars of the complaint.
Findings of the Panel
11.Therapeutic goods are defined in the Act to include goods that are represented in any way to be for therapeutic use, as well as goods “that are, whether because of the way in which the goods are presented or for any other reason, likely to be taken to be… for therapeutic use”. Therapeutic use is defined to include use in or in connection with preventing, diagnosing, curing or alleviating a disease, ailment, defect or injury in persons, or influencing, inhibiting, or modifying a physiological process in persons.
12.Section 42DL(1)(g) of the Act prohibits the publication of advertisements for therapeutic goods that are not included in the Register. The advertised product is not included in the Register, but was clearly represented to be for therapeutic use, in breach of section 42DL(1)(g) of the Act. The Panel therefore found this aspect of the complaint justified.
13.Section 4(1)(b) of the Code requires that advertisements for therapeutic goods “contain correct and balanced statements only and claims which the sponsor has already verified.” Section 4(2)(a) of the Code prohibits representations that are “likely to arouse unwarranted and unrealistic expectations of product effectiveness”. Section 4(2)(c) of the Code prohibits representations that “mislead directly or by implication or through emphasis, comparisons, contrasts or omissions”.
14.The advertiser provided no evidence to support the representations made in the advertisement. In the absence of any such evidence, the Panel was satisfied that the advertisement contained many representations that had not been verified, were not correct and balanced, were likely to arouse unwarranted and unrealistic expectations, and were misleading, in breach of these provisions.
15.These included the representations that the advertised product or its ingredients could offer “amazing results in the treatment of arthritis, rheumatoid and other joint pain”, is regarded as the most effective cure worldwide, can offer a life free of pain, helps to reverse the deterioration of cartilage, inhibits the autoimmune response, helps to reduce inflammation of the joints, has an anti-inflammatory effect, causes a reduction in joint pain “in a matter of days”, is “the most powerful remedy for chronic joint pain on the international market”, helps to prevent the surface of the cartilage from breaking down, contains natural anti-inflammatory agents that have a rapid calming effect, or stimulates the production of new cartilage and synovial fluid, together with the representations that “after 2 weeks [consumers] will experience less pain”, “after 4 weeks [consumers] will feel almost no pain in [their]
joints. The cartilage begins to rebuild and you will see a slight improvement in the joint lubrication”, “after 8 weeks, the pain in [consumers’] joints should disappear. The cartilage is being rebuilt and there is more joint lubrication”, “after 12 weeks, [consumers] not only will experience no more pain, but [their] joints should also move much smoother. The structuring of cartilage and joint lubrication are currently optimal”, and “after continuous use of Finitro Forte Plus, the recovery of the cartilage and a life free of pain are guaranteed”, and any representations that such effects had been demonstrated in “independent research”.
16.These aspects of the complaint were therefore justified.
17.Section 4(2)(g) of the Code prohibits representations that therapeutic goods are “infallible, unfailing, magical, miraculous”, or that they are “a certain, guaranteed or sure cure”. Section 4(2)(h) of the Code prohibits advertisements for therapeutic goods that “contain any claim, statement or implication that it is effective in all cases of a condition”.
18.The Panel was satisfied that the advertisement represented the advertised product to be unfailing, a guaranteed or sure cure and to be effective in all cases of several joint conditions.
19.These aspects of the complaint were therefore justified.
20.Section 4(5) of the Code requires that comparisons made in advertisements must be balanced and must not be misleading or likely to be misleading. In the absence of any evidence from the advertiser, the Panel was satisfied that the claims that the product is the “most effective cure worldwide” and “the most powerful remedy for chronic joint pain on the international market” were misleading.
21.This aspect of the complaint was therefore justified.
22.Section 5(2) of the Code prohibits advertisements that “refer, expressly or by implication, to serious forms of diseases, conditions, ailments or defects specified in Part 2 of Appendix 6, unless prior approval is given under the Therapeutic Goods Act 1989.” The diseases and conditions specified in Part 2 of Appendix 6 of the Code include “serious forms of” a wide range of health concerns.
23.The Panel was satisfied that the advertisement made reference to serious forms of musculoskeletal and immunological diseases, because it made unqualified reference to arthritis and rheumatoid arthritis.
24.This aspect of the complaint was therefore justified.
Sanctions
25.The Panel requests Finitro B.V., in accordance with subregulation 42ZCAI(1) of the Therapeutic Goods Regulations 1990:
a) to withdraw the advertisement from further publication;
b) to withdraw any representations that that the advertised product or its ingredients could offer “amazing results in the treatment of arthritis, rheumatoid and other joint pain”, is regarded as the most effective cure worldwide, can offer a life free of pain, helps to reverse the deterioration of cartilage, inhibits the autoimmune response, helps to reduce inflammation of the joints, has an anti-inflammatory effect, causes a reduction in joint pain “in a matter of days”, is “the most powerful remedy for chronic joint pain on the international market”, helps to prevent the surface of the cartilage from breaking down, contains natural anti-inflammatory agents that have a rapid calming effect, or stimulates the production of new cartilage and synovial fluid, together with the representations that “after 2 weeks [consumers] will experience less pain”, “after 4 weeks
[consumers] will feel almost no pain in [their] joints. The cartilage begins to rebuild and you will see a slight improvement in the joint lubrication”, “after 8 weeks, the pain in [consumers’] joints should disappear. The cartilage is being rebuilt and there is more joint lubrication”, “after 12 weeks, [consumers] not only will experience no more pain, but [their] joints should also move much smoother. The structuring of cartilage and joint lubrication are currently optimal”, and “after continuous use of Finitro Forte Plus, the recovery of the cartilage and a life free of pain are guaranteed”, any representations that such effects had been demonstrated in “independent research”, and any representations that refer to rheumatoid arthritis or make unqualified reference to arthritis;
c) not to use the representations in (b) above in any other advertisement*;
d) where the representation has been provided to other parties such as retailers or website publishers, and where there is a reasonable likelihood that the representation has been published or is intended to be published by such parties, to advise those parties that the representation(s) should be withdrawn; and,
e) within 14 days of being notified of this request, to provide evidence to the Panel of its compliance, including a response in writing that they will comply with the Panel’s sanctions,* and where appropriate, supporting material such as copies of instructions to advertising agents or publishers, or correspondence with retailers and other third party advertisers.
26.The advertiser’s attention is drawn to the provisions of sub-regulations 42ZCAI(3) and (4) which permit the Panel to make recommendations to the Secretary in the event of non-compliance with this request.
Dated 30 July 2013 For the Panel
Jason Korke Chairman
Appendix A: Definitions and footnotes
In this determination, unless otherwise specified:
a) “the Act” means the Therapeutic Goods Act 1989;
b) “the Regulations” means the Therapeutic Goods Regulations 1990; c) “the Code” means the Therapeutic Goods Advertising Code;
d) “the Register” means the Australian Register of Therapeutic Goods;
e) “any other advertisement” appearing in sub-regulation 42ZCA1(1)(d) is not confined to advertisements in specified or broadcast media (in relation to which complaints may be made to the Panel under Regulation 42ZCAB). It should be noted that HTML metatags and other information which can be retrieved by internet search engines, whether or not it is ordinarily viewed directly by consumers, constitutes advertisement material.
^Readers of the determination should note that the sections “complaint summary”, “the advertisement(s)”, “the complaint”, and “[a party]’s response to the complaint”, are summaries that are intended to aid readers of this document. In reaching its decision, the Panel considered all of the material before it, including material that may not be mentioned specifically in the summaries. The summaries do not form part of the Panel’s reasoning.
*Under regulation 42ZCAI of the Regulations, the Panel may request that a person apparently responsible for an advertisement withdraw a particular claim or representation, and give the Panel a written undertaking not to use the claim or representation in any other advertisement unless the person satisfies the Panel that the use of the representation would not result in a contravention of the Therapeutic Goods Act 1989, the Therapeutic Goods Regulations 1990 or the Therapeutic Goods Advertising Code. Under the Panel’s procedures, the Panel will not ordinarily give additional consideration to such a matter unless significant new material that was not available at the time of the Panel’s determination has become available, or until at least 12 months have passed since the Panel’s request was made.